Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941723

Authors

Syeda A Mina

Mohamed Shanshal

Konstantinos Leventakos

Kaushal Parikh

Affiliations

Soon will be listed here.

Abstract

Targeted therapies have changed the treatment landscape of non-small-cell lung cancer and led to improved patient survival across all stages of lung cancer. Newer advances in common and novel oncogenic drivers continue to occur at vigorous speed, making it challenging to stay up to date with the rapidly evolving field. In this article, we review the emerging perspectives in the treatment of actionable targets in lung cancer. We focus on the development of newer KRAS-directed therapies, particularly on non-G12C mutations, pan-RAS inhibitors, and RAS-GTP inhibitors. We also describe the current standard of care for EGFR- and ALK-altered NSCLC and dive into the novel treatments expected to be in the clinic soon. A similar approach is taken toward MET, HER2, RET, ROS1, and FGFR alterations as emerging targets in non-small-cell lung cancer. Finally, we conclude this review with the current body of evidence for targeting TROP-2 as a novel target, potentially of importance in post-targeted therapy scenarios.

References

Paz-Ares L, Juan-Vidal O, Mountzios G, Felip E, Reinmuth N, de Marinis F . Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024; 42(24):2860-2872. PMC: 11328920. DOI: 10.1200/JCO.24.00733. View

Xiang C, Guo L, Zhao R, Teng H, Wang Y, Xiong L . Identification and Validation of Noncanonical RET Fusions in Non-Small-Cell Lung Cancer through DNA and RNA Sequencing. J Mol Diagn. 2022; 24(4):374-385. DOI: 10.1016/j.jmoldx.2021.12.004. View

Timar J, Kashofer K . Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020; 39(4):1029-1038. PMC: 7680318. DOI: 10.1007/s10555-020-09915-5. View

Oh S, Lee Y, Lee E, Kim J, Park Y, Heo S . Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res. 2022; 29(1):221-232. DOI: 10.1158/1078-0432.CCR-22-2180. View

Roskoski Jr R . ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res. 2017; 121:202-212. DOI: 10.1016/j.phrs.2017.04.022. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Shimizu T, Sands J, Yoh K, Spira A, Garon E, Kitazono S . First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol. 2023; 41(29):4678-4687. PMC: 10564307. DOI: 10.1200/JCO.23.00059. View

Li Z, Song Z, Hong W, Yang N, Wang Y, Jian H . SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study. Signal Transduct Target Ther. 2024; 9(1):182. PMC: 11247081. DOI: 10.1038/s41392-024-01897-y. View

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

10.

Heist R, Guarino M, Masters G, Purcell W, Starodub A, Horn L . Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017; 35(24):2790-2797. DOI: 10.1200/JCO.2016.72.1894. View

11.

Zhou Z, Liu Z, Ou Q, Wu X, Wang X, Shao Y . Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. Cancer Biol Med. 2021; . PMC: 8185861. DOI: 10.20892/j.issn.2095-3941.2020.0120. View

12.

Moik F, Riedl J, Ay C . Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023; 35(3):327. DOI: 10.1016/j.annonc.2023.11.007. View

13.

Lin J, Horan J, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson M . NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov. 2024; 14(12):2367-2386. PMC: 11609626. DOI: 10.1158/2159-8290.CD-24-0231. View

14.

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

15.

Miura S, Yamanaka T, Kato T, Ikeda S, Horinouchi H, Ichihara E . Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clin Lung Cancer. 2020; 21(6):e592-e596. DOI: 10.1016/j.cllc.2020.05.011. View

16.

Lee G, Lee S, Oh D, Yu D, Jeong H, Kim J . MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. J Thorac Oncol. 2017; 12(8):1233-1246. DOI: 10.1016/j.jtho.2017.04.031. View

17.

de Langen A, Johnson M, Mazieres J, Dingemans A, Mountzios G, Pless M . Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10378):733-746. DOI: 10.1016/S0140-6736(23)00221-0. View

18.

Guerra E, Trerotola M, Aloisi A, Tripaldi R, Vacca G, La Sorda R . The Trop-2 signalling network in cancer growth. Oncogene. 2012; 32(12):1594-600. DOI: 10.1038/onc.2012.151. View

19.

Kim S, Yin J, Bohlman S, Walker P, Dacic S, Kim C . Characterization of Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clin Res Rep. 2022; 3(9):100381. PMC: 9445394. DOI: 10.1016/j.jtocrr.2022.100381. View

20.

Borgeaud M, Parikh K, Banna G, Kim F, Olivier T, Le X . Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. J Thorac Oncol. 2024; 19(7):973-983. DOI: 10.1016/j.jtho.2024.03.016. View